drugset
drugset / Trial / NCT01877889

A Study to Compare the Pharmacodynamics of Canagliflozin and Dapagliflozin in Healthy Volunteers

NCT01877889 ↗

Phase 1 Completed 60 enrolled Janssen-Cilag International NV
RandomizedCrossoverQuadruple-blindTreatment

Summary

The purpose of this study is to compare the pharmacodynamics (ie, how the drug affects the body) of canagliflozin with the pharmacodynamics of dapagliflozin.

Timeline

Start
2013-07
Primary completion
2014-03
Completion
2014-03

Drugs

EvaluationDrugModalityDoseRoute
Subject CANAGLIFLOZIN ANHYDROUS Small molecule 300 mg Oral
Subject Dapagliflozin Small molecule 10 mg Oral

Indications

No indication recorded.